YILIMART - Human TPO (25 μg)

Recombinant human TPO (Thrombopoietin) can be used to generate and expand hematopoietic stem cells. Megakaryocytes growth and development is also stimulated by TPO, and

in vivo

it regulates the level of circulating platelets thus, it is crucial for megakaryocytopoiesis and thrombopoiesis. Recombinant human TPO is optimized for use in cell culture, differentiation studies, and functional assays.

Applications

Human TPO can be used for a variety of applications, including:

Megakaryocyte proliferation and differentiation in vitro .
In vitro expansion of CD34⁺ hematopoietic progenitor cells.
Differentiation of ES-derived cells towards the hematopoietic lineage.
In vitro platelet activation.
Apoptosis assays.

Alternative names

MDGF

Background information

Thrombopoietin (TPO), also known as thrombopoiesis stimulating factor (TSF), is a glycoprotein hormone and the major stimulator of megakaryopoiesis and platelet production. TPO is expressed in liver, kidney, spleen, lung, bone marrow, and brain. The TPO receptor is a product of the proto-oncogene

c-mpl

and displays homology with type I cytokine receptor superfamily members. Analogous to the effect of erythropoietin (EPO), the primary mode of action of TPO is inhibition of apoptosis of its target cells. By contrast, TPO is strongly proapoptotic in the brain and acts as a counterpart of EPO which has neuroprotective properties.

Quality description

Research-grade

cytokines are suitable for a wide variety of cell culture applications. They are sterile-filtered prior to lyophilization. Generally, endotoxin levels are <0.1 ng/μg (<1 EU/μg), and purities are >95%. The biological activity is tested in appropriate bioassays.

Premium-grade

cytokines offer the convenience of high and well-defined biological activities and allow exact unit dosing for demanding applications. The biological activity is determined after lyophilization and reconstitution, and normalized to WHO/NIBSC standards whenever available. In general, endotoxin levels are <0.01 ng/μg (<0.1 EU/μg), and purities are >97%. Lot-specific certificates of analysis are available on request (macstec@miltenyibiotec.de).

Biological activity

Proliferation of MO7e cells (NIBSC 03/124)
premium grade: ≥ 1×

10
⁷
U/mg

(typical activity: ≥ 3×

10
⁷
U/mg

)
research grade: ≥ 5×

10
⁶
U/mg

Figure 1
View details

Figure 1

Mass spectrometry analysis (ESI-MS) of Human TPO, premium grade. The second RP-HPLC peak corresponds to the calculated molecular mass of 18832 Da with N-terminal formyl-methionine.

Mass spectrometry analysis (ESI-MS) of Human TPO, premium grade. The second RP-HPLC peak corresponds to the calculated molecular mass of 18832 Da with N-terminal formyl-methionine.
Figure 2
View details

Figure 2

Mass spectrometry analysis (ESI-MS) of Human TPO, premium grade. The first RP-HPLC peak corresponds to the calculated molecular mass of 18804 Da with N-terminal methionine.

Mass spectrometry analysis (ESI-MS) of Human TPO, premium grade. The first RP-HPLC peak corresponds to the calculated molecular mass of 18804 Da with N-terminal methionine.
Figure 3
View details

Figure 3

SDS-PAGE of Human TPO, research grade under reduced (R) and non-reduced (NR) conditions.

SDS-PAGE of Human TPO, research grade under reduced (R) and non-reduced (NR) conditions.
Figure 4
View details

Figure 4

Human TPO biological activity.
The biological activity of Human TPO, research grade is determined by proliferation assay using MO7e cells.

Human TPO biological activity.
The biological activity of Human TPO, research grade is determined by proliferation assay using MO7e cells.
Figure 5
View details

Figure 5

Human TPO biological activity.
Activity of Human TPO, research grade, (red bar) was compared to another commercially available product (black bar).

Human TPO biological activity.
Activity of Human TPO, research grade, (red bar) was compared to another commercially available product (black bar).

Selected references
1. Laurenti, E. et al. (2015) CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 16(3): 302-313
2. Brault, J. et al. (2014)
  
  Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells:
  ex vivo
  models of X
  ⁰
  -linked, AR22
  ⁰
  - and AR47
  ⁰
  - chronic granulomatous diseases.
  
  Biores Open Access 3(6): 311-326
3. Steinleitner, K. et al. (2012) EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. Anticancer Res. 32(11): 4883-4889
Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

查看数据文件查看下载

Human TPO (25 μg)

For research use only

您浏览过的商品

Applications

Alternative names

Background information

Quality description

Biological activity

Figure 1

Figure 1

Figure 2

Figure 2

Figure 3

Figure 3

Figure 4

Figure 4

Figure 5

Figure 5

Selected references

Certificates

相关产品